VC-6771September 24, 2026 · 2 min

Ruxolitinib Cream Hit 79% Response Rate in HS Phase 2 Trial

A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now under…